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Abstract
Background
Hyperglycemia following solid organ transplant is common among patients without pre-
existing diabetes mellitus (DM). Post-transplant hyperglycemia can occur once or multiple
times, which if continued, causes new-onset diabetes after transplantation (NODAT).
Objective
To study if the first and recurrent incidence of hyperglycemia are affected differently by immu-
nosuppressive regimens, demographic and medical-related risk factors, and inpatient hyper-
glycemic conditions (i.e., an emphasis on the time course of post-transplant complications).
Methods
We conducted a retrospective analysis of 407 patients who underwent kidney transplanta-
tion at Mayo Clinic Arizona. Among these, there were 292 patients with no signs of DM prior
to transplant. For this category of patients, we evaluated the impact of (1) immunosuppres-
sive drugs (e.g., tacrolimus, sirolimus, and steroid), (2) demographic and medical-related
risk factors, and (3) inpatient hyperglycemic conditions on the first and recurrent incidence
of hyperglycemia in one year post-transplant. We employed two versions of Cox regression
analyses: (1) a time-dependent model to analyze the recurrent cases of hyperglycemia and
(2) a time-independent model to analyze the first incidence of hyperglycemia.
Results
Age (P = 0.018), HDL cholesterol (P = 0.010), and the average trough level of tacrolimus
(P<0.0001) are significant risk factors associated with the first incidence of hyperglycemia,
while age (P<0.0001), non-White race (P = 0.002), BMI (P = 0.002), HDL cholesterol (P =
0.003), uric acid (P = 0.012), and using steroid (P = 0.007) are the significant risk factors for
the recurrent cases of hyperglycemia.
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Discussion
This study draws attention to the importance of analyzing the risk factors associated with a
disease (specially a chronic one) with respect to both its first and recurrent incidence, as
well as carefully differentiating these two perspectives: a fact that is currently overlooked in
the literature.
Introduction
Hyperglycemia is a well-described complication following solid organ transplantation [1–3].
Among patients without a prior history of diabetes mellitus (DM), hyperglycemia that either
persists after transplant, or which resolves but later recurs and persists, is termed new onset
diabetes after transplant (NODAT). Hyperglycemia and NODAT are strong predictors of graft
failure and cardiovascular mortality occurring commonly after solid organ transplant [1–3].
The occurrence of hyperglycemia or development of NODAT have been attributed to many
factors, including (1) immunosuppressive drugs and their diabetogenic effects, (2) other demo-
graphic and medical-related risk factors, and (3) inpatient hyperglycemic conditions.
Regarding the first factor, Table 1 summarizes studies on the diabetogenic effect of anti-
rejection agents (e.g., tacrolimus, sirolimus, cyclosporine, glucocorticoids, and steroid) with
respect to different solid organ transplantations (e.g., kidney, liver, and pancreas). The main
insights from this literature are related to: (1) the efficacy of a drug in preventing organ rejec-
tion while imposing less risk for hyperglycemia or NODAT, (2) the relative benefits/side effects
of two or more drugs when compared with each other, and (3) the potentials of drugs when
switching from one therapy to another.
In addition to immunosuppressive drugs, the literature has analyzed other demographic or
medical-related risk factors to establish possible statistically significant associations with hyper-
glycemia and NODAT (Table 2). The majority of the literature in this stream attempts to (1)
derive associations between risk factor(s) and a continuous variable (linear regression models)
that represents hyperglycemia/NODAT status (e.g., blood glucose level measured by hemoglo-
bin A1c and fasting plasma glucose tests), (2) demonstrate the same effect for a categorical vari-
able (i.e., whether a patient suffers from hyperglycemia or not, at a specific point of time) by
applying logistic regression models, or (3) discuss the probability of survival from hyperglyce-
mia/NODAT at a single point of time (Cox regression models).
Furthermore, recent evidence indicates that hyperglycemia occurring in the immediate
post-transplant period (i.e., during the post-operative hospital stay) is also associated with
NODAT [67, 68].
Table 1. Classification of literature based on diabetogenic effect of immunosuppressive drugs.
Drug Type Organ Type Selected References
Tacrolimus Kidney/Liver [4–18]
Sirolimus Kidney/Liver [17, 19–26]
Cyclosporine Kidney [18, 27–37]
Glucocorticoids Kidney/Pancreas [18, 38–44]
Steroid Kidney/Pancreas [45–48]
doi:10.1371/journal.pone.0142363.t001
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In spite of all these efforts, none of these factors (immunosuppressive drugs and their diabe-
togenic effects, demographic and medical-related risk factors, and inpatient hyperglycemic
conditions) have been analyzed with respect to the time course of post-transplant complica-
tions. Specifically, one critical aspect that is overlooked by the literature is an understanding
and analysis of remitting and relapsing hyperglycemia in post-solid organ transplant recipients.
Such an understanding can be critical because (1) the insights gained can be quite different
from those previously known for the incidence of hyperglycemia and (2) these insights can be
extended to other chronic diseases with the possibility of remitting and relapsing, such as can-
cer and multiple sclerosis. To the best of our knowledge, this is the first study analyzing the
first and recurrent incidence of hyperglycemia. In particular, utilizing a population of renal
transplant recipients who had no history of DM before transplantation, we undertake a set of
analyses to determine which contributing factors are significantly associated with the first inci-
dence, and which ones are significantly associated with the recurrent incidence.
Materials and Methods
Study Cohort
After obtaining Mayo Clinic Institutional Review Board (Mayo Clinic IRB) approval (Continuing
Review #: PR13-004295-01) and written informed consent from all participating patients, this
study conducts an analysis of 292 patients who underwent a renal transplant between 1999 and
2006 in Mayo Clinic Arizona, and who had no history of DM prior to surgery. Briefly, all patients
were monitored at the time of transplant as well as month 1, 4, and 12 post-transplant. The avail-
able data included (1) demographic data such as age, race, and gender, (2) baseline patient charac-
teristics including body mass index (BMI), blood pressure (BP), total cholesterol (Chol), high-
density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), uric acid (UA),
and triglyceride (TG), (3) type of immunosuppressive drugs and diabetes medications that were
used by the patients, (4) trough level of tacrolimus (as the main immunosuppressive drug used in
this study), and (5) results of fasting plasma glucose (FPG) and Hemoglobin A1c (HbA1c) tests as
measures of glycemic control. All major abbreviations used in this study are explained in Table 3.
Definitions
NODAT was defined as HbA1c 6.5%, or FPG 126 mg/dL, or the requirement of diabetes
medications (e.g., insulin or oral agent) after patient discharge from hospital [67, 68]. We apply
this criteria to determine the incidence of post-transplant hyperglycemia, which may happen
just once or for multiple times (recurrent). We refer to either of these conditions as instances of
remitting and relapsing hyperglycemia.
Table 2. Classification of literature based on the impact of risk factors on hyperglycemia and NODAT.
Risk Factor Organ Type Selected References
Age Kidney/Liver [49–57]
Gender Kidney/Liver [53, 54, 57–62]
Race/Ethnicity Kidney [49, 52, 54, 57, 63, 64]
BMI Kidney/Liver [49–51, 53–57, 64]
Cadaveric organ Kidney/Liver [50, 51, 53–55, 57]
Hepatitis C Virus Kidney/Liver [49, 51, 53, 55, 57, 64]
Hypertension Kidney [52, 55, 64–66]
Diabetes History Kidney [49, 53, 57, 64, 66]
doi:10.1371/journal.pone.0142363.t002
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Statistical Methods
We now explain the statistical inference methods we employed to analyze the effects of immu-
nosuppressive drugs, the corresponding risk factors, and the inpatient period conditions on the
first and recurrent incidence of post-transplant hyperglycemia. The statistical models used
were: (i) The Cox regression model with time-dependent covariates, which measures the pro-
portional hazard imposed on the response variable (hyperglycemia incidence) by covariates
that change over time. For example, the BMI of a patient may change as his/her weight changes
(Chol, HDL, and LDL are some other examples of such covariates). As another example,
whether the patient uses an immunosuppressive drug at a specific time or not can be consid-
ered as a time-dependent covariate. Therefore, we sought to fully comprehend the effect of
these changing behaviors on the recurrent incidence of hyperglycemia. (ii) Cox regression
model with time-independent covariates, which measures the proportional hazard imposed on
the response variable (the first incidence of hyperglycemia) by covariates at the time of the first
incidence of hyperglycemia. (iii) Kaplan-Meier survival analysis to characterize the cumulative
probability of experiencing hyperglycemia over time.
The statistical analyses also includemultiple imputations by chained equations (MICE) [69],
which we used to replace some missing data (with the prevalence of less than 10% in our data set)
with validated values. We conducted all statistical analyses by using the R computing package.
Results
Demographic and Baseline Characteristics of Patients
Among 407 patients in the study cohort, there were 115 patients with the history of diabetes.
The remaining 292 patients had no indication of diabetes prior to or at the time of their trans-
plants. The average age of patients who had no diabetes before transplant was 49.7 years, while
those who had diabetes before had the average age of 56. Table 4 summarizes the demographic
data along with some other baseline characteristics of patients.
Incidence of Hyperglycemia
Regarding the definition of remitting and relapsing hyperglycemia, Table 5 summarizes differ-
ent hyperglycemic states that can occur after renal transplantation. Therefore, 79 (27.06%)
patients experienced remitting and relapsing post-transplant hyperglycemia (and hence the
hyperglycemia for the first time). Among these patients, 19+3+1+24 = 47 patients experienced
Table 3. Description of abbreviations used in this study.
Abbreviation Description
HG Hyperglycemia
FPG Fasting plasma glucose
HbA1c Hemoglobin A1c
C0 Trough level of tacrolimus
BMI Body mass index
BP Blood pressure
Chol Total cholesterol
HDL High-density lipoprotein cholesterol
LDL Low-density lipoprotein cholesterol
TG Triglyceride
UA Uric acid
doi:10.1371/journal.pone.0142363.t003
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hyperglycemia multiple times, while 20+11+1 = 32 had it just once. As an example of the
potential remitting and relapsing nature of post-transplant hyperglycemia, there are 11 patients
who developed hyperglycemia at 4 months, which resolved at 12 months.
Summary of Immunosuppressive Treatment Regimens
This section sheds light on information about main immunosuppressive medications that have
been considered for this study (tacrolimus, steroid, and sirolimus). As mentioned before, we
focus on 292 patients with no prior history of diabetes.
Tacrolimus. Tacrolimus (Prograf) is the main immunosuppressive drug utilized in this
study. Fig 1 (the first three columns) demonstrates the number of patients at month 1, 4, and
12 using tacrolimus, which include 283, 275, and 270 patients (out of 292 patients), respec-
tively. As our primary interest in this study is to analyze the incidence of hyperglycemia, we
further classified patients in terms of whether they experienced hyperglycemia at a specific
time or not, and Fig 1 reveals this information as well.
Another important point regarding tacrolimus is the dosage goals and achieved levels at dif-
ferent points of time. Tacrolimus goals are adjusted to avoid toxicity and to the lowest dose
possible to avoid rejection per clinical standards of care. This is a standard clinical practice and
is based on individual response and pharmacokinetics. Table 6 summarizes this information. It
should be noted that the achieved levels of tacrolimus are represented in terms of the average
trough level of tacrolimus.
Table 4. Demographic and baseline characteristics of patients at the time of transplant.
Characteristics Diabetes History (n = 115) No Diabetes History (n = 292)
Age (year) 56.0 ± 10.4a 49.7 ± 14.6
Gender: Male (%) 61.74 56.16
Race: Whiteb (%) 59.13 75.34
BMI (kg/m2) 28.7 ± 5.4 27.0 ± 5.6
Donor: Livec (%) 52.17 67.47
Pre-transplant FPG (mg/dL) 143.8 ± 52.3 92.8 ± 11.3
Pre-transplant HbA1c (%) 6.9 ± 1.5 5.5 ± 0.3
Pre-transplant UA (mg/dL) 6.3 ± 2.3 6.6 ± 2.1
Pre-transplant Chol(mg/dL) 183.0 ± 47.4 181.9 ± 46.0
Pre-transplant HDL (mg/dL) 50.6 ± 16.0 50.6 ± 16.0
Pre-transplant LDL (mg/dL) 94.2 ± 33.0 93.9 ± 34.8
Pre-transplant TG (mg/dL) 191.2 ± 94.7 179.0 ± 87.7
a mean ± standard deviation,
b versus non-white (including Native American, Hispanic, and Black races),
c versus cadaveric.
doi:10.1371/journal.pone.0142363.t004
Table 5. Percentage of patients satisfying the criteria.
Time Having the criteria?
Month 1 No Yes No No Yes Yes No Yes
Month 4 No No Yes No Yes No Yes Yes
Month 12 No No No Yes No Yes Yes Yes
# of patients (%) 213 (72.95) 20 (6.85) 11 (3.77) 1 (0.34) 19 (6.51) 3 (1.03) 1 (0.34) 24 (8.22)
doi:10.1371/journal.pone.0142363.t005
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Steroid. Steroid is the second main immunosuppressive drug incorporated in this study.
Fig 1 (the second three columns) illustrates the number of patients at month 1, 4, and 12 using
steroid, which include 138, 147, and 140 patients (out of 292 patients), respectively. This shows
that in comparison with tacrolimus which was used by the majority of patients, fewer patients
used steroid. (According to what explained for tacrolimus, the percentages of patients using
tacrolimus at months 1, 4, and 12 were 283/292 = 97%, 275/292 = 94%, and 270/292 = 92%,
respectively.) Fig 1 also shows the number of patients who used steroid and experienced
hyperglycemia.
Steroid is usually prescribed by the following mechanism. If after using induction steroids
(which last for up to 5 days post-transplant) a patient has an organ rejection, she will receive a
taper dose of steroid (i.e., slow withdrawal). Then, by 1 month post-transplant, the patient will
be put on the maintenance regimen of 5 mg daily (which is a low dosage), unless the patient
has another rejection(s) later and needs possibly extra dosage of steroid therapy. To this end,
we observed the following from the data set: (1) Among the 292 patients, only 20 patients had
organ rejection at month 1, and hence, had to use a taper dose of steroid at this month. There-
fore, there remained 272 patients who had no rejection during month 1. (2) Among 20 patients
at month 1, 4 patients at month 4 and 1 patient at month 12 experienced organ rejection (these
were mutually exclusive patients). (3) Among 272 patients at month 1, 5 patients at month 4
and 6 patients at month 12 experienced organ rejection (these were mutually exclusive
patients). Therefore, according to the mechanism explained before, it can be concluded that 4
+5+1+6 = 16 patients (out of 292) had increased dose of steroid (i.e., more than 5 mg daily)
after 1 month post-transplant. Furthermore, as explained before, according to Fig 1, 138, 147,
and 140 patients used steroid at months 1, 4, and 12, respectively. Therefore, 138-(4+1) = 133,
Fig 1. Number of patients who used immunosuppressive drugs at months 1, 4, and 12. Such patients are further classified as having hyperglycemia
(HG) or not at that specific time points.
doi:10.1371/journal.pone.0142363.g001
Table 6. Tacrolimus goals and achieved levels (average trough level) at months 1, 4, and 12.
Time point Tacrolimus goal Tacrolimus achieved average trough level
1 month 10–12 mg/dL 11.88 mg/dL
4 months 8–10 mg/dL 9.59 mg/dL
12 months 6–8 mg/dL 7.83 mg/dL
doi:10.1371/journal.pone.0142363.t006
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147-(4+5) = 138, and 140-(1+6) = 133 patients remained on the regimen of 5 mg daily at
months 1, 4, and 12, respectively.
Sirolimus. Sirolimus (Rapamune) is the third main immunosuppressive drug incorporated
in this study. Fig 1 shows that sirolimus was utilized by a very small proportion of patients.
Time-Dependent Cox Regression Model: Recurrent Incidence of
Hyperglycemia
To address events that may occur repeatedly, such as the repeated occurrence of hyperglyce-
mia, we need to incorporate covariates that change over time (e.g., BMI, BP, etc.). To this end,
we employed a Cox regression model with time-dependent covariates and recurrent events,
where each event is assumed to occur once a patient meets the criteria defined in Table 5. The
performance measure in this model is the hazard ratio (HR), such that if mean HR 1, the
corresponding covariate will have a positive effect on the response variable (and vice versa).
According to Table 7 (Part I), induction immunosuppressive agents (thymoglobulin and
simulect) and steroids were significantly associated with lower and higher chance of recurrent
hyperglycemia, respectively. However, neither using tacrolimus nor its average trough level
was significantly associated with the repeated occurrence of hyperglycemia. Therefore, one
cannot establish the diabetogenic effect of tacrolimus when hyperglycemia occurs repeatedly.
As we will see in the next section, this finding is in a sharp contrast with the case where only
the first incident of hyperglycemia is considered.
Time-Independent Cox Regression Model: First Incidence of
Hyperglycemia
The reason that the diabetogenic effect of tacrolimus cannot be established when hyperglyce-
mia is occurring repeatedly may be due to the fact that tacrolimus dosage is usually reduced
with the passage of time after transplant (see Table 6). To test this hypothesis, we analyzed the
immunosuppressive effect when hyperglycemia happens for the first time. We used a time-
independent Cox regression model, in which only covariates at the time of first occurrence are
considered. According to Table 7 (Part II), the average trough level of tacrolimus is signifi-
cantly associated with a higher chance of first hyperglycemia incident, which implies that the
diabetogenic effect of tacrolimus can be established in this case. This observation highlights the
importance of differentiating between the first and recurrent incidents of hyperglycemia.
As other observations made in this regard, induction immunosuppressive agents (thymo-
globulin and simulect) are significantly associated with lower chance of first hyperglycemia.
However, we cannot establish any significant association between using steroid and the first
incidence of hyperglycemia. This can be due to the fact that high dosages of steroid were only
considered for a small proportion of patients in month 1 post-transplant (see section “Sum-
mary of Immunosuppressive Treatment Regimens” for more information).
Kaplan-Meier Analysis: Hyperglycemia Incidence
The results of time-independent analysis established by the Cox regression model shows the
significant association between the average trough level of tacrolimus and the first incidence of
hyperglycemia. Here, we aim to use Kaplan-Meier survival analysis to calculate the probability
of having hyperglycemia obtained from Kaplan-Meier survival curves.
To this end, we consider the main stratum based on average trough level of tacrolimus clas-
sified as “10” and “>10” mg/dL. In order to fully comprehend the effect of these levels on the
incidence of hyperglycemia, we conduct unadjusted (univariate) analysis as well as ten adjusted
Remitting and Relapsing Hyperglycemia in Post-Renal Transplant
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analyses for those risk factors mentioned before. However, to incorporate these risk factors
into the Kaplan-Meier survival analysis, they should be discretized in classes, which are shown
in Table 8. It should be noted that the classification thresholds for each of these risk factors
have been set so as to distinguish the groups in terms of health-related risks (e.g., BMI of 30 kg/
m2 for obesity). Furthermore, except age, gender, race, and blood pressure, other thresholds
have been obtained from [70]. Regarding the blood pressure, if the systolic and diastolic blood
pressure are “<120” and “<80” mmHg, respectively, the patient is normal. Otherwise, the
patient has hypertension. These thresholds have been obtained from [71].
Fig 2 presents the above-mentioned survival curves. For simplicity, patients with an average
tacrolimus trough level of less than or equal to (more than) 10 mg/dL are said to have Trough-
Table 7. Effect of immunosuppressive drugs on hyperglycemia: The results of two statistical inferencemethods (numbers in bold represent statis-
tically significant covariates at 95% confidence level).
Covariates Part I: Time-dependent Part II: Time-independent
Mean HR Lower CIa Upper CI P-valueb Mean HR Lower CI Upper CI P-value
Simulectc (unadje) 0.51 0.274 0.953 0.035 0.655 0.299 1.437 0.291
Simulect (adjf) 0.267 0.131 0.543 0.000 0.444 0.190 1.036 0.060
Thymoglobulinc (unadj) 0.68 0.480 0.950 0.025 0.645 0.401 1.038 0.071
Thymoglobulin (adj) 0.658 0.458 0.947 0.024 0.640 0.388 1.055 0.080
Avg. C0 (unadj) 0.993 0.859 1.147 0.924 1.949 1.793 2.120 0.000
Avg. C0 (adj) 0.992 0.859 1.146 0.912 1.982 1.788 2.197 0.000
Tacrolimusd (unadj) 0.922 0.434 1.963 0.834 1.285 0.470 3.512 0.625
Tacrolimus (adj) 0.689 0.297 1.601 0.387 1.156 0.397 3.370 0.790
Sirolimusd (unadj) 1.329 0.655 2.694 0.431 0.834 0.305 2.279 0.723
Sirolimus (adj) 1.786 0.852 3.745 0.124 0.810 0.280 2.344 0.697
Steroidd (unadj) 1.230 0.894 1.691 0.204 1.248 0.803 1.939 0.325
Steroid (adj) 1.562 1.131 2.158 0.007 1.441 0.900 2.305 0.128
a 95% confidence interval,
b P-values are obtained based on standard Normal distribution,
c An immunosuppressive agent: Induction therapy,
d An immunosuppressive agent: Maintenance therapy,
e Unadjusted (univariate) analysis,
f All adjusted analyses were done based on age, race, gender, BMI, BP, Chol, HDL, LDL, UA, and TG.
doi:10.1371/journal.pone.0142363.t007
Table 8. Description of groups formed by risk factors.
Risk Factors Unit Group 0 Group 1
Age Years <50  50
Gender — Female Male
Race — White non-White
BMI kg/m2 <30 (non-obese) 30 (obese)
BP — Normal Hypertension
Chol mg/dL <200 200
HDL mg/dL 40 <40
LDL mg/dL <130 130
TG mg/dL <150 150
UA mg/dL <7.3 7.3
doi:10.1371/journal.pone.0142363.t008
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Fig 2. Kaplan-Meier survival curves: Cumulative probability of experiencing hyperglycemia (%) as a result of having different average trough
levels of tacrolimus:10mg/dL vs. >10mg/dL. In all parts (A)-(K), the P-value by the Logrank test is <0.0001. (+ represents censored events.). (A)
Unadjusted (univariate) analysis. (B) Adjusted analysis with age. (C) Adjusted analysis with race. (D) Adjusted analysis with gender. (E) Adjusted analysis
with BMI. (F) Adjusted analysis with BP. (G) Adjusted analysis with Chol. (H) Adjusted analysis with HDL. (I) Adjusted analysis with LDL. (J) Adjusted
analysis with UA. (K) Adjusted analysis with TG.
doi:10.1371/journal.pone.0142363.g002
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level 0 (1). Fig 2A shows that Trough-level 1 patients have significantly higher chance of
experiencing hyperglycemia (HG) than Trough-level 0 patients (i.e., Logrank P<0.0001). Spe-
cifically, almost all of the former group experience HG by month 4 (i.e., probability of
experiencing HG 100%), while the latter group still have about 80% chance of not experienc-
ing HG by year 1. Although we made these observations for the unadjusted (univariate) analy-
sis, the same behavior can be seen for adjusted analyses: the chance of experiencing HG is
significantly different (i.e., Logrank P<0.0001) across groups formed by different risk factors
(see Fig 2B–2K). Furthermore, Trough-level 1 patients with any of the following conditions
almost certainly experience HG by month 1: non-White ethnicity, obese (BMI>30 kg/m2),
and LDL130 mg/dL. Moreover, Trough-level 1 patients with any of the following conditions
experience HG by month 1 with a chance not less than 90%: age>50, male, hypertension, Chol
200 mg/dL, HDL<40 mg/dL, UA7.3 mg/dL, or TG150 mg/dL.
Other Risk Factors for the Incidence of Hyperglycemia
We also analyzed the associations of other well-known risk factors for both the first and recur-
rent incidence of hyperglycemia. To this end, we again applied two types of Cox regression
model. The results of these analyses are provided in Table 9. We found that age and HDL were
significantly associated with the first incident of hyperglycemia, whereas age, race (non-White),
BMI, HDL, and UA were significant risk factors for the recurrent incidence of hyperglycemia.
Combining these results with those in Table 7, it can be stated that the first incidence of
hyperglycemia is more attributed to the diabetogenic effect of tacrolimus. However, in the
absence of such an effect, the recurrent incidence of hyperglycemia is mainly imputed to other
risk factors (e.g., age, race (non-White), BMI, HDL, and UA). A review of Tables 7 and 9 also
shows potential consequences of choosing the right statistical tool in determining the diabeto-
genic effect of immunosuppressive drugs or corresponding risk factors for hyperglycemia inci-
dence. In addition, observing that the first and recurrent types of hyperglycemia are subject to
different risk factors might have broader implications for other similar chronic diseases. The
current literature largely overlooks time-dependent analyses, and our results shed light on the
importance of closing this gap.
Table 9. Risk factors that affect the incidence of hyperglycemia.
Risk Factors Part I: Time-dependent Part II: Time-independent
Mean HR Lower CIa Upper CI P-valueb Mean HR Lower CI Upper CI P-value
Age 1.044 1.031 1.056 0.000 1.022 1.004 1.040 0.018
Race: Non-Whitec 1.769 1.234 2.536 0.002 1.195 0.707 2.019 0.506
Gender: Male 1.108 0.738 1.661 0.621 1.105 0.658 1.854 0.706
BMI 1.048 1.017 1.079 0.002 0.976 0.932 1.023 0.314
BP 1.001 0.987 1.015 0.903 0.996 0.979 1.014 0.672
Chol 1.001 0.995 1.008 0.699 1.007 0.998 1.015 0.133
HDL 0.976 0.960 0.992 0.003 0.972 0.950 0.993 0.010
LDL 0.995 0.987 1.003 0.204 0.997 0.986 1.007 0.509
UA 0.833 0.722 0.961 0.012 0.829 0.680 1.010 0.063
TG 1.002 1.000 1.004 0.145 1.002 0.999 1.004 0.206
a 95% confidence interval,
b P-values are obtained based on standard Normal distribution,
c Including Native American, Hispanic, and Black.
doi:10.1371/journal.pone.0142363.t009
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Impact of the Inpatient Period
Prior studies have addressed the importance of the inpatient period: what happens to patients
during post-transplant hospitalization may have an impact on patient’s conditions after hospi-
tal discharge [67, 68]. To evaluate the impact of inpatient period, we analyzed the effect of (1)
average bed glucose result (bed.avg), which is obtained by a poke test, (2) average blood glucose
result (blood.avg), and (3) inpatient hyperglycemia (in.hyp) on the incidence of hyperglycemia.
Table 10 summarizes the results obtained from our statistical methods. Based on Table 10, the
average bed and blood glucose results are significantly associated with both the first and the
recurrent incidence of hyperglycemia. However, the occurrence of inpatient hyperglycemia is
only associated with recurrent incidence of hyperglycemia.
Discussion
Our analyses highlight the complex nature of post-renal transplant hyperglycemia. Some
patients never exhibit hyperglycemia, some develop permanent hyperglycemia (NODAT),
while for others hyperglycemia may be transient or even recurrent. Hyperglycemia and
NODAT have been mostly analyzed for a short period after transplantation [72, 73]. However,
their incidence may be underestimated by such short-term studies (see [74–79] for some stud-
ies analyzing long-term analyses). Our results show that if the diabetogenic effect of immuno-
suppressive drugs is of interest, short-term analyses might be preferred, while long-term
analyses are more suitable when studying other risk factors.
The idea of analyzing hyperglycemia from this perspective (i.e., time course of complications)
can also be extended to other chronic diseases in which both the first incident and the recurrent
ones need to be monitored. For example, prostate cancer and breast cancer are among diseases
that may show signs only once or may do so from time to time with periods of remission in
between [80, 81]. For this category of diseases, considering both time-dependent and time-inde-
pendent analyses (as we did in this study) may provide new and important insights.
There are some limitations in our study. First, due to the nature of our study, having
patients’ information on a more regular basis (e.g., monthly) would improve the accuracy of
our results. Second, if the data set included patients’ information after the first year post-
Table 10. Effect of inpatient period on hyperglycemia incidence.
Inpatient Parameters Part I: Time-dependent Part II: Time-independent
Mean HR Lower CIa Upper CI P-valueb Mean HR Lower CI Upper CI P-value
bed.avge (unadjc) 1.029 1.024 1.035 0.000 1.023 1.013 1.032 0.000
bed.avg (adjd) 1.024 1.018 1.030 0.000 1.018 1.008 1.029 0.000
blood.avgf (unadj) 1.031 1.023 1.038 0.000 1.022 1.011 1.033 0.000
blood.avg (adj) 1.024 1.016 1.032 0.000 1.018 1.007 1.030 0.002
in.hypg (unadj) 3.509 1.557 7.908 0.002 2.162 0.874 5.347 0.095
in.hyp (adj) 2.496 1.080 5.768 0.032 1.543 0.613 3.885 0.358
a 95% confidence interval,
b P-values are obtained based on standard Normal distribution,
c Unadjusted (univariate) analysis,
d All adjusted analyses were done based on age, race, gender, BMI, BP, Chol, HDL, LDL, UA, and TG,
e Average bed glucose result,
f Average blood glucose result,
g Inpatient hyperglycemia.
doi:10.1371/journal.pone.0142363.t010
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transplant, we would be able to conduct a more robust Cox regression and Kaplan-Meier sur-
vival analysis. Third, although, according to Table 5, 79 patients (who experienced post-trans-
plant hyperglycemia for the first time) are sufficient for the purpose of our analyses, it might be
a relatively small sample. Finally, even though sirolimus and steroid were used for the minority
of patients (in comparison with tacrolimus), we had no information about the exact dosages
and trough levels of these two drugs. Otherwise, we could also evaluate the possible association
between their trough levels and incidence of hyperglycemia.
Finally, some of our findings may not be generalizable to other types of solid organ trans-
plants (e.g., heart, liver, and pancreas). Therefore, testing our findings can be a fruitful path for
future research. By extending the idea of this study and incorporating the time course of com-
plications for other organs, one can establish a holistic framework to analyze (a) the diabeto-
genic effect of immunosuppressive drugs, and (b) the effect of other risk factors.
Conclusion
We analyzed the effects of (1) immunosuppressive drugs, (2) risk factors, and (3) inpatient
hyperglycemia on the first and recurrent incidence of post-transplant hyperglycemia in
patients who had no history of diabetes mellitus prior to their transplants. We employed two
statistical inference methods: (1) Cox regression model with time-dependent covariates to ana-
lyze hyperglycemia with recurrence and (2) Cox regression model with time-independent
covariates to evaluate the first incidence of hyperglycemia. We also employed Kaplan-Meier
survival analysis to characterize the cumulative probability of experiencing post-transplant
hyperglycemia over time.
Based on the results obtained from these methods, we can state that the diabetogenic effect
of tacrolimus (based on its trough level) can be established when hyperglycemia is experienced
for the first time. However, in a sharp contrast, this effect cannot be established for the recur-
rent incidents of hyperglycemia. This difference might be due to the fact that tacrolimus dosage
is reduced by physicians over time. As the diabetogenic effect is ruled out, our results show that
age, race (non-White), BMI, HDL, steroid use, and uric acid are the only significant risk factors
for the recurrent incidence.
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